Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catheter Precision (VTAK) Free Cash Flow (2017 - 2025)

Catheter Precision (VTAK) has disclosed Free Cash Flow for 9 consecutive years, with -$2.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow rose 21.1% to -$2.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$9.7 million, a 15.67% decrease, with the full-year FY2024 number at -$9.4 million, up 54.74% from a year prior.
  • Free Cash Flow was -$2.2 million for Q3 2025 at Catheter Precision, up from -$2.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$1.7 million in Q2 2024 to a low of -$12.1 million in Q1 2023.
  • A 5-year average of -$4.6 million and a median of -$3.0 million in 2022 define the central range for Free Cash Flow.
  • Biggest YoY gain for Free Cash Flow was 83.76% in 2024; the steepest drop was 51.7% in 2024.
  • Catheter Precision's Free Cash Flow stood at -$5.7 million in 2021, then skyrocketed by 46.65% to -$3.0 million in 2022, then soared by 37.31% to -$1.9 million in 2023, then tumbled by 51.7% to -$2.9 million in 2024, then rose by 24.51% to -$2.2 million in 2025.
  • Per Business Quant, the three most recent readings for VTAK's Free Cash Flow are -$2.2 million (Q3 2025), -$2.3 million (Q2 2025), and -$2.3 million (Q1 2025).